Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Yabao Pharmaceutical Group

Status and phase: Completed; Phase 1

Conditions: Sepsis

Treatments: Drug: SY-005

Study type: Interventional

Funder types: Industry

Identifiers

NCT04217629

SY005001

Details and patient eligibility

About

This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.

Full description

This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic study of a single-dose/multiple-doses incremental intravenous injection of SY-005（recombinant human annexin A5） in healthy subjects. Six sigle-dose group trials are planned: 0.75mg, 2.5mg, 5mg, 10mg, 15mg,and 20mg and three multiple-doses groups are planned: 5mg, 10mg and 20mg. Single-dose groups are planned to enroll 64 subjects and multiple-doses groups are planned to enroll 30 subjects.

Enrollment: 96 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults aged 18-65 (including two values);
• During the screening period, the body weight of male subjects is greater than or equal to 50kg, and that of female subjects is greater than or equal to 45kg, with a body mass index (BMI = weight/height squared (kg/m2)) in the range of 18 to 26 (including both ends);
• Medical history, physical examination, other laboratory examination items and examination related to the test before the test. All the tests were normal or not clinically significant mild abnormalities, clinical research doctors judged that qualified;
• APTT and PT laboratory test results in coagulation function are within the normal range;
• Platelet laboratory examination results are not lower than the lower limit of normal range；
• The venous channel is normal and blood samples can be fully collected according to the plan;
• Subjects must give informed consent to this study before the study and voluntarily sign a written informed consent;
• Subjects are willing to take effective contraceptive measures, and have pregnancy plane during and within 3 months after the stud. Female subjects should be non-lactating, have negative pregnancy test, or have no fertility potential. Women who have been without a uterus for at least 12 months or are considered to have no potential pregnancy.

Exclusion criteria

• The subjects are suffering from cardiovascular diseases, respiratory diseases, gastrointestinal diseases, liver and kidney function damage, endocrine diseases, blood system diseases, nervous system diseases, which can significantly change the distribution, metabolism and excretion of test drugs, or the use of test drugs will increase the risk of subjects or affect the analysis of research results;
• QTc interval is not in normal range, male higher than 450 msec and female higher than 470 msec;
• Those who have a history of drug or other allergies, or may be allergic to the study drug or any component of the study drug in the judgment of the researcher;
• Those who completed or withdrawed from a clinical study within 3 months of the screening period, or is currently conducting a clinical study. Or participated in other medical research activities, which the researchers judged unsuitable for this study;
• Have a history of alcohol abuse and drug abuse;
• Those who have donated blood within 3 months, or those who plan to donate blood within 3 months, or those who have transfused blood within 4 weeks before the study;
• Women who consume more than 14 g of alcohol a week and men who consume more than 21 g of alcohol (1 g of alcohol is equivalent to360 mL of beer, 150 mL of wine or 45 mL of liquor) a week;Participants were reluctant to stop drinking between 24 hours before the study began and the end of the study;
• Those who smoke more than 5 cigarettes a day or are unwilling/unable to stop nicotine intake during the study period;
• Abnormal chest X-ray examination with clinical significance;
• 12-lead ecg showed clinically significant abnormalities, and the researcher believed that participating in the experiment would increase the risk of subjects;
• Viral serological evidence during screening: patients with positive hepatitis B surface antigen (HBsAg), positive anti-hcv, or positive anti-HIV antibodyof human immunodeficiency virus (HIV), or positive anti-tp antibody of treponema pallidum;
• Patients who have undergone major surgery within 6 months before drug administration;
• Those who have been screened for the first 4 weeks or plan to receive live vaccines during the trial;
• Fertile eligible subjects (male and female) will not agree to use a reliable contraceptive method (hormone or barrier method or abstinence) during the study period and at least 1 months after administration;
• The sponsor or the investigator decides that the investigator is not suitable to participate in the study; Women who have been without a uterus for at least 12 months or are considered to have no potential pregnancy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

96 participants in 9 patient groups, including a placebo group

SY-005 single-dose 0.75mg

Experimental group

Description:

4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.

Treatment:

Drug: SY-005

SY-005 single-dose 2.5mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.

Treatment:

Drug: SY-005

SY-005 single-dose 5mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.

Treatment:

Drug: SY-005

SY-005 single-dose 10mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.

Treatment:

Drug: SY-005

SY-005 single-dose 15mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.

Treatment:

Drug: SY-005

SY-005 single-dose 20mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.

Treatment:

Drug: SY-005

SY-005 multiple-doses 5mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.

Treatment:

Drug: SY-005

SY-005 multiple-doses 10mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.

Treatment:

Drug: SY-005

SY-005 multiple-doses 20mg

Placebo Comparator group

Description:

This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.

Treatment:

Drug: SY-005